Journal of Pharmaceutical Innovation

, Volume 6, Issue 4, pp 232–240 | Cite as

Studies on Flash Evaporation for Preparation of Porous Solid Dispersions Using Piroxicam as a Model Drug

  • Manish Dhall
  • Sanju Nanda
  • A. K. MadanEmail author
Research Article


An amalgamation of solid dispersion and capillarity has been attempted in present study for enhancement of dissolution rate of poorly soluble drugs. Flash evaporation technique was utilized for enhancement of the dissolution rate of piroxicam. One of the major problems with this drug is its very low solubility in biological fluids, which results in poor bioavailability after oral administration. An attempt was made to enhance the dissolution rate of piroxicam by converting it into porous solid dispersion by flash evaporation method using polyvinylpyrrolidone (PVP) 40,000 as a water-soluble carrier. The resulting solid dispersions were characterized by DSC, FTIR, and X-ray diffraction. In vitro dissolution study revealed significant improvement of dissolution profile of piroxicam. The release of drug from porous solid dispersions containing PVP was superior to those of marketed product, conventional nonporous solid dispersion prepared by solvent evaporation method and drug alone. The steep increase in dissolution rate of porous form is attributable to combined effect of solid dispersion and capillarity.


Piroxicam Solid dispersion Polyvinylpyrrolidone Dissolution rate Flash evaporation Capillarity 



Thanks are due to Bangia Pharmaceuticals, Karnal (Haryana), India, for providing gift sample of piroxicam. Thanks are also due to Jubilant Organosys Ltd., Noida, Uttar Pradesh, India, for providing facilities to carry out DSC, FTIR, and XRD studies.

Declaration of Interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.


  1. 1.
    Myrdal PB, Yalkowsky SH. Solubilization of drugs in aqueous media. In: Swarbrick J, Boylan JC, editors. Encyclopedia of Pharmaceutical Technology. New York: Marcel Dekker; 2002. p. 2458–80.Google Scholar
  2. 2.
    Chiou WL, Riegalman S. Pharmaceutical applications of solid dispersion systems. J Pharm Sci. 1971;60(9):1281–302.PubMedCrossRefGoogle Scholar
  3. 3.
    Serajuddin ATM. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems and recent breakthroughs. J Pharm Sci. 1999;88(10):1058–66.PubMedCrossRefGoogle Scholar
  4. 4.
    Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm. 2000;50:47–60.PubMedCrossRefGoogle Scholar
  5. 5.
    Borne RF. Non-steroidal anti-inflammatory drugs. In: Foye WO, Lembe TL, Williams DA, editors. Principles of medicinal chemistry. New Delhi: Waverly Private Limited; 1999. p. 567–9.Google Scholar
  6. 6.
    Martindale. Aspirin and similar analgesics and anti-inflammatory agents. In: Reynolds JEF, Prasad AB, editors. The Extra Pharmacopoeia. London: The Pharmaceutical Press Publication; 1989. pp. 31–32.Google Scholar
  7. 7.
    Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413–20.PubMedCrossRefGoogle Scholar
  8. 8.
    Clark DE. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena.1.Prediction of intestinal absorption. J Pharm Sci. 1999;88:807–14.PubMedCrossRefGoogle Scholar
  9. 9.
    Lebenberg R, Amidon GL. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New approaches to international regulatory standards. Eur J Pharm Biopharm. 2000;50:3–12.CrossRefGoogle Scholar
  10. 10.
    Roberts LJ, Morrow JD. Analgesic–antipyretic and anti-inflammatory agents and drugs employed in treatment of gout. In: Hardman JG, Limbird LE, Gilman AG, editors. Goodman and Gilman’s, The Pharmacological Basis of Therapeutics. New York: Mc Graw Hill; 1992. p. 713–4.Google Scholar
  11. 11.
    Patel DM, Shah RP, Jogani PD. Tablet formulation of piroxicam containing PVP K-30 and sodium lauryl sulphate. Indian J Pharm Sci. 2004;66(1):49–55.Google Scholar
  12. 12.
    United States Pharmacopoeia XXVI, National Formulary XXI. Asian Edn. Rockville, MD: US Pharmacopoeial Convention; 2003. pp. 2227–2229.Google Scholar
  13. 13.
    United States Pharmacopoeia XXV, National Formulary XX. Asian Edn. Rockville, MD: US Pharmacopoeial Convention; 2002. pp. 1388–1389.Google Scholar
  14. 14.
    Krile B, Caplar V, Kajfez F. Blazevic N. In: Florey K, editor. Analytical profiles of drug substances and excipients. New York: Academic; 1986. p. 509–31.Google Scholar
  15. 15.
    Tantishaiyakul V, Kaewnopparat N, Ingkatawornwong S. Properties of solid dispersions of piroxicam in polyvinylpyrrolidone. Int J Pharm. 1999;181:143–51.PubMedCrossRefGoogle Scholar
  16. 16.
    Ingkatawornwong S, Kaewnopparat N, Tantishaiyakul V. Studies on aging piroxicam polyvinylpyrrolidone solid dispersions. Pharmazie. 2001;56(3):227–30.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Faculty of Pharmaceutical Sciences, Pt. B. D. SharmaUniversity of Health SciencesRohtakIndia
  2. 2.Faculty of Pharmaceutical SciencesM.D. UniversityRohtakIndia

Personalised recommendations